VIEKIRA XR

PeakSM

dasabuvir sodium; ombitasvir; paritaprevir; ritonavir

AbbVie
NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Jan 2, 2035
107 months away
Patent Expiry
Jan 2, 2035

Patent Records (5)

Patent #ExpiryTypeUse Code
8501238
Sep 17, 2028
SubstanceProduct
U-1636
9139536
Nov 9, 2028
U-1753
8188104
May 17, 2029
SubstanceProduct
U-1636
8642538
Sep 10, 2029
SubstanceProduct
U-1638
9006387
Jun 10, 2030
U-1687
Company
AbbVie
AbbVie
NORTH CHICAGO, IL
1495 open jobs
External Resources
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers